Dyne Therapeutics Inc   (DYN)
Other Ticker:  
Price: $13.4600 $-0.82 -5.742%
Day's High: $14.255 Week Perf: 0.22 %
Day's Low: $ 13.07 30 Day Perf: -5.74 %
Volume (M): 579 52 Wk High: $ 15.63
Volume (M$): $ 7,789 52 Wk Avg: $11.64
Open: $14.22 52 Wk Low: $4.75

 Market Capitalization (Millions $) 763
 Shares Outstanding (Millions) 57
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -177
 Cash Flow (TTM) (Millions $) 33
 Capital Exp. (TTM) (Millions $) 2

Dyne Therapeutics Inc
We are a holding company and conduct substantially all of our business operations through our subsidiaries. Our current business operations are focused primarily in three areas of the energy industry: power generation; natural gas liquids; and regulated energy delivery.

   Company Address: 1560 Trapelo Road Waltham 2451 MA
   Company Phone Number: 786-8230   Stock Exchange / Ticker: NASDAQ DYN
   DYN is expected to report next financial results on August 03, 2023.

Customers Net Income grew by DYN's Customers Net Profit Margin grew to

209.9 %

25.69 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
AEP        0.28% 
CEG        3.85% 
DTE        2.34% 
EXC        0.98% 
NRG        2.34% 
XEL        0.49% 
• View Complete Report

Aridis Pharmaceuticals Inc

Redemption of Losses due to Decrease in orders at the ARDS amid the fiscal interval ending March 31 2023

Investors in Aridis Pharmaceuticals Inc. (ARDS) are in for a rough ride as recent financial results suggest that the company is not in a good financial position. In the fiscal timeframe closing March 31, 2023, the company reported a per-share loss of $-0.22 - a stark contrast to positive earnings experienced by other pharmaceutical companies in the same period.
The decrease in turnover resulted in fading revenue, leading to a larger shortfall. ARDS's revenue dropped by a staggering 8.846% to $1.08 million YoY. This decrease in revenue is alarming as it suggests that there are underlying issues that the company is struggling to address. Revenue is the lifeblood of businesses, and the fact that ARDS's revenue has taken such a significant hit speaks volumes about the company's struggles.

Lifecore Biomedical Inc

Lifecore Biomedical Inc released Revenue of $27.6 million, in the December to February 26 2023

The pharmaceutical industry is a vital sector in the global economy. It is responsible for producing lifesaving drugs, vaccines, and other medical products that improve the lives and health of people globally. However, like any other industry, the pharmaceutical industry also faces its own set of challenges. These challenges range from regulatory and compliance issues to stiff competition and changing market dynamics.
Recently, one of the major pharmaceutical companies shared some good news. The company proclaimed record revenues of $27.6 million in the fiscal year ending February 26, 2023. This achievement is commendable, considering the challenges the pharmaceutical industry faces. However, another company in the sector, Lifecore Biomedical Inc, reported a net deficit of $-40.192 million in the same reporting season.

Globestar Therapeutics Corporation

The Major Pharmaceutical Preparations company caused good story for the stock market, exhibiting a relevant gain in Mar 31 2023 report with operating shortfall of $-0.142059 million

The financial results for the Globestar Therapeutics Corporation (GSTC) for the January to March 31, 2023 reporting cycle have been released, and shareholders were not expecting any moderations at the top-line. However, it appears that they are paying a significant amount of attention to the company's operating shortfall, which was reported at $-0.142059 million during the same period. One positive aspect of this result is that it compares favorably to the performance of the second quarter of 2022, where the operating shortfall was significantly higher at $-0.66231 million. This appears to be a significant indicator for the company's course going forward.
For a company like GSTC, which is on an upward trajectory in terms of revenue generation, it becomes increasingly important to run cost-effectively in order to reach the next chapter of its growth. The good news is that there has been some alleviation on the bottom-line, as the diminishing returns have been cut from the same time frame a year prior. The fiscal span ending in the second quarter of 2023 saw a loss of $-0.150 million, which is lower than the loss of $-0.689 million reported in the same period in 2022. This is a major takeaway from the most recent financial results, which indicates that GSTC is moving in the right direction, albeit at a steady pace.

Q Biomed Inc

The company has Turned into Profitability at the Major Pharmaceutical Preparations company in the fourth quarter of 2022 earnings season

For the fourth quarter of 2022 earnings season Q Biomed Inc had turn a round to surplus by exhibiting earnings per share of $0.02 per share compare to $-0.08 a year before and earnings per share turned positive from $-0.03 per share from the prior financial reporting period. The revenue went down sharply by -88.053 % to $0.01 million from $0.10 million in the comparable financial reporting period a year before and sequentially Revenue Tumbled by -52.286 % from $0.03 million.

23andme Holding Co

Redemption of Diminishing Returns at ME amid the fourth quarter of 2023 earnings season

23andme Holding Co Posts Mixed Q4 Results, Despite Lower Demand
23andme Holding Co, the popular genetic testing company, has released its latest earnings report for Q4 2023. In a disappointing development for investors, the company's revenue was hit hard by lower demand, leading to a vanishing revenue and higher deficit.
While the earnings report may have been mixed, there was some positive news to report. The company announced that it had been able to decrease its loss per share to $-0.13 per share, which may be seen as an encouraging sign to some investors. However, revenue decreased by -8.137% to $92.38 million, signifying that the company still has some way to go in order to generate more growth.


Dyne Therapeutics Inc's Segments
Coal Power generation
 Segment     of total Revenue
 Segment     of total Revenue
Gas Power generation
 Segment     of total Revenue
Total Power Generation
 Segment     of total Revenue
• View Complete Report

Dyne Therapeutics Inc's Operating Statistics Decrease / Increase
Coal thousands Megawatt Hours Generated    Coal thousands Megawatt Hours Generated Growth   
IPH thousands Megawatt Hours Generated   IPH thousands Megawatt Hours Generated Decline   
Gas thousands Megawatt Hours Generated    Gas thousands Megawatt Hours Generated Growth   
Total thousands Megawatt Hours Generated    Total thousands Megawatt Hours Generated Growth   
North Path Average Power Prices ($/MWh)    North Path Average Power Prices ($/MWh) Growth   
Commonwealth Edison Average Power Prices ($/MWh)    Commonwealth Edison Average Power Prices ($/MWh) Growth   
PJM West Average Power Prices ($/MWh)    PJM West Average Power Prices ($/MWh) Growth   
New York Zone A Average Power Prices ($/MWh)     
New York Zone G Average Power Prices ($/MWh)     
Mass Hub Power Prices ($/MWh)   Mass Hub Power Prices ($/MWh) Decline   


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071